The impact of antibiotic use on the incidence and resistance pattern of extended-spectrum beta-lactamase-producing bacteria in primary and secondary healthcare settings

British Journal of Clinical Pharmacology

Volumn 74, Issue 1, 2012, Pages 171-179

  Aldeyab, Mamoon A ^a,c   Harbarth, Stephan ^b   Vernaz, Nathalie ^b   Kearney, Mary P ^c   Scott, Michael G ^c   Darwish Elhajji, Feras W ^d   Aldiab, Motasem A ^e   Mcelnay, James C ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c NORTHERN HEALTH AND SOCIAL CARE TRUST   (United Kingdom)

^d Private University   (Jordan)

^e KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

Antibiotic stewardship; ESBL; Fluoroquinolones restriction policy; Time series analysis

Indexed keywords

AMINOGLYCOSIDE; AMOXICILLIN PLUS CLAVULANIC ACID; CARBAPENEM; CEPHALOSPORIN; CIPROFLOXACIN; GLYCOPEPTIDE; IMIDAZOLE DERIVATIVE; LINCOSAMIDE; MACROLIDE; NITROFURAN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULFONAMIDE; TETRACYCLINE; TRIMETHOPRIM;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; COMORBIDITY; DRUG USE; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; HEALTH CARE POLICY; HOSPITAL PATIENT; HUMAN; INCIDENCE; PRIMARY HEALTH CARE; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION; ANTI-BACTERIAL AGENTS; BACTERIA; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; CROSS INFECTION; DISINFECTANTS; FLUOROQUINOLONES; HOSPITALS; HUMANS; INCIDENCE; MULTIVARIATE ANALYSIS; PRIMARY HEALTH CARE; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84862128157     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2011.04161.x     Document Type: Article

References (30)

1. Pitout JD, Laupland KB. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 2008; 8: 159-66.
2. Falagas ME, Karageorgopoulos DE. Extended-spectrum beta-lactamase-producing organisms. J Hosp Infect 2009; 73: 345-54.
3. Ramphal R, Ambrose PG. Extended-spectrum beta-lactamases and clinical outcomes: current data. Clin Infect Dis 2006; 42: (SUPPL. 4): S164-72.
4. Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev 2005; 18: 657-86.
5. Pfaller MA, Segreti J. Overview of the epidemiological profile and laboratory detection of extended-spectrum beta-lactamases. Clin Infect Dis 2006; 42: (SUPPL. 4): S153-63.
6. Rodríguez-Baño J, Navarro MD, Romero L, Muniain MA, Cueto M, Gálvez J, Perea EJ, Pascual A. Risk-factors for emerging bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Clin Microbiol Infect 2008; 14: 180-3.
7. Kaier K, Frank U, Hagist C, Conrad A, Meyer E. The impact of antimicrobial drug consumption and alcohol-based hand rub use on the emergence and spread of extended-spectrum beta-lactamase-producing strains: a time-series analysis. J Antimicrob Chemother 2009; 63: 609-14.
8. MacDougall C, Powell JP, Johnson CK, Edmond MB, Polk RE. Hospital and community fluoroquinolone use and resistance in Staphylococcus aureus and Escherichia coli in 17 US hospitals. Clin Infect Dis 2005; 41: 435-40.
9. Gallini A, Degris E, Desplas M, Bourrel R, Archambaud M, Montastruc JL, Lapeyre-Mestre M, Sommet A. Influence of fluoroquinolone consumption in inpatients and outpatients on ciprofloxacin-resistant Escherichia coli in a university hospital. J Antimicrob Chemother 2010; 65: 2650-7.
10. Vernaz N, Huttner B, Muscionico D, Salomon JL, Bonnabry P, López-Lozano JM, Beyaert A, Schrenzel J, Harbarth S. Modelling the impact of antibiotic use on antibiotic-resistant Escherichia coli using population-based data from a large hospital and its surrounding community. J Antimicrob Chemother 2011; 66: 928-35.
11. Dellit TH, Owens RC, McGowan JE Jr, Gerding DN, Weinstein RA, Burke JP, Huskins WC, Fishman NO, Carpenter CF, Brennan PJ, Billeter M, Hooton TM, Infectious Diseases Society of America, Society for Healthcare Epidemiology of America. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007; 44: 159-77.
12. MacDougall C, Polk RE. Antimicrobial stewardship programs in health care systems. Clin Microbiol Rev 2005; 18: 638-56.
13. Gottesman BS, Carmeli Y, Shitrit P, Chowers M. Impact of quinolone restriction on resistance patterns of Escherichia coli isolated from urine by culture in a community setting. Clin Infect Dis 2009; 49: 869-75.
14. Aldeyab MA, Devine MJ, Flanagan P, Mannion M, Craig A, Scott MG, Harbarth S, Vernaz N, Davies E, Brazier JS, Smyth B, McElnay JC, Gilmore BF, Conlon G, Magee FA, Elhajji FW, Small S, Edwards C, Funston C, Kearney MP. Multi-hospital outbreak of Clostridium difficile ribotype 027 infection: epidemiology and analysis of control measures. Infect Control Hosp Epidemiol 2011; 32: 210-9.
15. Shardell M, Harris AD, El-Kamary SS, Furuno JP, Miller RR, Perencevich EN. Statistical analysis and application of quasi experiments to antimicrobial resistance intervention studies. Clin Infect Dis 2007; 45: 901-7.
16. Aldeyab MA, Monnet DL, López-Lozano JM, Hughes CM, Scott MG, Kearney MP, Magee FA, McElnay JC. Modelling the impact of antibiotic use and infection control practices on the incidence of hospital-acquired methicillin-resistant Staphylococcus aureus: a time-series analysis. J Antimicrob Chemother 2008; 62: 593-600.
17. Aldeyab MA, Harbarth S, Vernaz N, Kearney MP, Scott MG, Funston C, Savage K, Kelly D, Aldiab MA, McElnay JC. Quasiexperimental study of the effects of antibiotic use, gastric acid-suppressive agents, and infection control practices on the incidence of Clostridium difficile-associated diarrhea in hospitalized patients. Antimicrob Agents Chemother 2009; 53: 2082-8.
18. Leigh DA, Williams JD. Method for the detection of significant bacteriuria in large groups of patients. J Clin Pathol 1964; 17: 498-503.
19. Tobacman JK. Assessment of comorbidity: a review. Clin Perform Qual Health Care 1994; 2: 23-32.
20. WHO Collaborating Center for Drug Statistics Methodology. Guidelines for ATC Classifications and Ddds Assignment. Oslo: WHO Collaborating Center, 2002.
21. Helfenstein U. Box-Jenkins modelling in medical research. Stat Methods Med Res 1996; 5: 3-22.
22. McGowan JE Jr. Antimicrobial resistance in hospital organisms and its relation to antibiotic use. Rev Infect Dis 1983; 5: 1033-48.
23. McCorry A, Damani N, Rajendran R, McCaffrey P, Muckian D, Loughran P. Reducing the use of 'high-risk' antibiotics through implementation of an antibiotic stewardship programme. BJ Clin Pharm 2010; 2: 341-4.
24. Vernaz N, Sax H, Pittet D, Bonnabry P, Schrenzel J, Harbarth S. Temporal effects of antibiotic use and hand rub consumption on the incidence of MRSA and Clostridium difficile. J Antimicrob Chemother 2008; 62: 601-7.
25. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, Saunders LD, Beck CA, Feasby TE, Ghali WA. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005; 43: 1130-9.
26. Davey P, Brown E, Fenelon L, Finch R, Gould I, Hartman G, Holmes A, Ramsay C, Taylor E, Wilcox M, Wiffen P. Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database Syst Rev 2005; (4): CD003543.
27. Lipsitch M. The rise and fall of antimicrobial resistance. Trends Microbiol 2001; 9: 438-44.
28. Harris AD, Lautenbach E, Perencevich E. A systematic review of quasi-experimental study designs in the fields of infection control and antibiotic resistance. Clin Infect Dis 2005; 41: 77-82.
29. Rawat D, Nair D. Extended-spectrum β-lactamases in gram negative bacteria. J Glob Infect Dis 2010; 2: 263-74.
30. Aldeyab MA, Kearney MP, McElnay JC, Magee FA, Conlon G, Gill D, Davey P, Muller A, Goossens H, Scott MG, ESAC Hospital Care Subproject Group. A point prevalence survey of antibiotic prescriptions: benchmarking and patterns of use. Br J Clin Pharmacol 2011; 71: 293-6.